In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on BELLUS Health (BLU – Research Report), with a price target of $16.00. The company's shares closed last Wednesday at $6.78. According to TipRanks.com, Fein is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -22.6% and a 20.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Amylyx Pharmaceuticals Inc, and Global Blood Therapeutics. BELLUS Health has an analyst consensus of Strong Buy, with a price target consensus of $16.56.
https://www.tipranks.com/news/blurbs/h-c-wainwright-reiterates-a-buy-rating-on-bellus-health-blu?utm_source=advfn.com&utm_medium=referral
Blue Chip Value Fund, Inc. (NYSE:BLU)
Historical Stock Chart
From Mar 2023 to Apr 2023 Click Here for more Blue Chip Value Fund, Inc. Charts.
Blue Chip Value Fund, Inc. (NYSE:BLU)
Historical Stock Chart
From Apr 2022 to Apr 2023 Click Here for more Blue Chip Value Fund, Inc. Charts.